key: cord-0776707-9bvetodx
authors: Brümmer, Lukas E.; Katzenschlager, Stephan; Gaeddert, Mary; Erdmann, Christian; Schmitz, Stephani; Bota, Marc; Grilli, Maurizio; Larmann, Jan; Weigand, Markus A.; Pollock, Nira R.; Macé, Aurélien; Carmona, Sergio; Ongarello, Stefano; Sacks, Jilian A.; Denkinger, Claudia M.
title: Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review and meta-analysis
date: 2021-08-12
journal: PLoS Med
DOI: 10.1371/journal.pmed.1003735
sha: 3a7ed200260218a673a52e1858e6d1b6ea7242fc
doc_id: 776707
cord_uid: 9bvetodx

BACKGROUND: SARS-CoV-2 antigen rapid diagnostic tests (Ag-RDTs) are increasingly being integrated in testing strategies around the world. Studies of the Ag-RDTs have shown variable performance. In this systematic review and meta-analysis, we assessed the clinical accuracy (sensitivity and specificity) of commercially available Ag-RDTs. METHODS AND FINDINGS: We registered the review on PROSPERO (registration number: CRD42020225140). We systematically searched multiple databases (PubMed, Web of Science Core Collection, medRvix, bioRvix, and FIND) for publications evaluating the accuracy of Ag-RDTs for SARS-CoV-2 up until 30 April 2021. Descriptive analyses of all studies were performed, and when more than 4 studies were available, a random-effects meta-analysis was used to estimate pooled sensitivity and specificity in comparison to reverse transcription polymerase chain reaction (RT-PCR) testing. We assessed heterogeneity by subgroup analyses, and rated study quality and risk of bias using the QUADAS-2 assessment tool. From a total of 14,254 articles, we included 133 analytical and clinical studies resulting in 214 clinical accuracy datasets with 112,323 samples. Across all meta-analyzed samples, the pooled Ag-RDT sensitivity and specificity were 71.2% (95% CI 68.2% to 74.0%) and 98.9% (95% CI 98.6% to 99.1%), respectively. Sensitivity increased to 76.3% (95% CI 73.1% to 79.2%) if analysis was restricted to studies that followed the Ag-RDT manufacturers’ instructions. LumiraDx showed the highest sensitivity, with 88.2% (95% CI 59.0% to 97.5%). Of instrument-free Ag-RDTs, Standard Q nasal performed best, with 80.2% sensitivity (95% CI 70.3% to 87.4%). Across all Ag-RDTs, sensitivity was markedly better on samples with lower RT-PCR cycle threshold (Ct) values, i.e., <20 (96.5%, 95% CI 92.6% to 98.4%) and <25 (95.8%, 95% CI 92.3% to 97.8%), in comparison to those with Ct ≥ 25 (50.7%, 95% CI 35.6% to 65.8%) and ≥30 (20.9%, 95% CI 12.5% to 32.8%). Testing in the first week from symptom onset resulted in substantially higher sensitivity (83.8%, 95% CI 76.3% to 89.2%) compared to testing after 1 week (61.5%, 95% CI 52.2% to 70.0%). The best Ag-RDT sensitivity was found with anterior nasal sampling (75.5%, 95% CI 70.4% to 79.9%), in comparison to other sample types (e.g., nasopharyngeal, 71.6%, 95% CI 68.1% to 74.9%), although CIs were overlapping. Concerns of bias were raised across all datasets, and financial support from the manufacturer was reported in 24.1% of datasets. Our analysis was limited by the included studies’ heterogeneity in design and reporting. CONCLUSIONS: In this study we found that Ag-RDTs detect the vast majority of SARS-CoV-2-infected persons within the first week of symptom onset and those with high viral load. Thus, they can have high utility for diagnostic purposes in the early phase of disease, making them a valuable tool to fight the spread of SARS-CoV-2. Standardization in conduct and reporting of clinical accuracy studies would improve comparability and use of data.

a1111111111 a1111111111 a1111111111 a1111111111 a1111111111

As the COVID-19 pandemic continues around the globe, antigen rapid diagnostic tests (Ag-RDTs) for SARS-CoV-2 are seen as an important diagnostic tool to fight the virus's spread [1, 2] . The number of Ag-RDTs on the market is increasing constantly [3] . Initial data from independent evaluations suggest that the performance of SARS-CoV-2 Ag-RDTs may be lower than what is reported by the manufacturers. In addition, Ag-RDT accuracy seems to vary substantially between tests [4] [5] [6] .

With the increased availability of Ag-RDTs, an increasing number of independent validations have been published. Such evaluations differ widely in their quality, methods, and results, making it difficult to assess the true performance of the respective tests [7] . To inform decision makers on the best choice of individual tests, an aggregated, widely available, and frequently updated assessment of the quality, performance, and independence of the data is urgently needed. While other systematic reviews have been published, they include data only up until November 2020 [8] [9] [10] [11] , exclude preprints [12] , or were industry sponsored [13] . In addition, only 1 assessed the quality of studies in detail, with data up until November 2020 [7, 11] .

With our systematic review and meta-analysis, we aim to close this gap in the literature and link to a website (https://www.diagnosticsglobalhealth.org) that is regularly updated.

We developed a study protocol following standard guidelines for systematic reviews [14, 15] , which is available in S1 Text. We also completed the PRISMA checklist (S1 PRISMA Checklist). Furthermore, we registered the review on PROSPERO (registration number: CRD42020225140).

We performed a search of the databases PubMed, Web of Science, medRxiv, and bioRxiv using search terms that were developed with an experienced medical librarian (M. Grilli) using combinations of subject headings (when applicable) and text-words for the concepts of the search question. The main search terms were "Severe Acute Respiratory Syndrome Corona-virus 2," "COVID-19," "Betacoronavirus," "Coronavirus," and "Point of Care Testing." The full list of search terms is available in S2 Text. We also searched the Foundation for Innovative New Diagnostics (FIND) website (https://www.finddx.org/sarscov2-eval-antigen/) for relevant studies manually. We performed the search up until 30 April 2021. No language restrictions were applied.

We included studies evaluating the accuracy of commercially available Ag-RDTs to establish a diagnosis of SARS-CoV-2 infection, against reverse transcription polymerase chain reaction (RT-PCR) or cell culture as reference standard. We included all study populations irrespective of age, presence of symptoms, or study location. We considered cohort studies, nested cohort studies, case-control or cross-sectional studies, and randomized studies. We included both peer-reviewed publications and preprints.

We excluded studies in which patients were tested for the purpose of monitoring or ending quarantine. Also, publications with a population size smaller than 10 were excluded. Although the size threshold of 10 is arbitrary, such small studies are more likely to give unreliable estimates of sensitivity and specificity.

Ag-RDTs for SARS-CoV-2 aim to detect infection by recognizing viral proteins. Most Ag-RDTs use specific labeled antibodies attached to a nitrocellulose matrix strip, to capture the virus antigen. Successful binding of the antibodies to the antigen either is detected visually (through the appearance of a line on the matrix strip [lateral flow assay]) or requires a specific reader for fluorescence detection. Microfluidic enzyme-linked immunosorbent assays have also been developed. Ag-RDTs typically provide results within 10 to 30 minutes [6] .

Viral culture detects viable virus that is relevant for transmission but is available in research settings only. Since RT-PCR tests are more widely available and SARS-CoV-2 RNA (as reflected by RT-PCR cycle threshold [Ct] value) highly correlates with SARS-CoV-2 antigen quantities, we considered it an acceptable reference standard for the purposes of this systematic review [16] . It is of note that there is currently no international standard for the classification of viral load available. per paper (SK, CE, SS, or MB) and controlled by a second (LEB, SK, SS, or MB). Any differences were resolved by discussion or by consulting a third author (CMD).

We differentiated between clinical accuracy studies (performed on clinical samples) and analytical accuracy studies (performed on spiked samples with a known quantity of virus). Analytical accuracy studies can differ widely in methodology, impeding an aggregation of their results. Thus, while we extracted the data for both kinds of studies, we only considered data from clinical accuracy studies as eligible for the meta-analysis. Separately, we summarized the results of analytical studies and compared them with the results of the meta-analysis for individual tests.

The quality of the clinical accuracy studies was assessed by applying the QUADAS-2 tool [17] . The tool evaluates 4 domains: patient selection, index test, reference standard, and flow and timing. For each domain, the risk of bias is analyzed using different signaling questions. Beyond the risk of bias, the tool also evaluates the applicability of each included study to the research question for every domain. The QUADAS-2 tool was adjusted to the needs of this review and can be found in S3 Text.

We examined whether a study received financial support from a test manufacturer (including the free provision of Ag-RDTs), whether any study author was affiliated with a test manufacturer, and whether a respective conflict of interest was declared. Studies were judged not to be independent from the test manufacturer if at least 1 of these aspects was present; otherwise, they were considered to be independent.

We extracted raw data from the studies and recalculated performance estimates where possible based on the extracted data. The raw data can be found in S2 Table. We prepared forest plots for the sensitivity and specificity of each test and visually evaluated the heterogeneity between studies. If 4 or more datasets were available with at least 20 positive RT-PCR samples per dataset for a predefined analysis, a meta-analysis was performed. We report point estimates of sensitivity and specificity for SARS-CoV-2 detection compared to the reference standard along with 95% confidence intervals (CIs) using a bivariate model (implemented with the "reitsma" command from the R package "mada," version 0.5.10). When there were fewer than 4 studies for an index test, only a descriptive analysis was performed, and accuracy ranges are reported. In subgroup analyses where papers presented data only on sensitivity, a univariate randomeffects inverse variance meta-analysis was performed (using the "metagen" command from the R package "meta," version 4.11-0). We predefined subgroups for meta-analysis based on the following characteristics: Ct value range, sampling and testing procedure in accordance with manufacturer's instructions as detailed in the instructions for use (IFU) (henceforth called IFU-conforming) versus not IFU-conforming, age (<18 versus �18 years), sample type, presence or absence of symptoms, symptom duration (<7 days versus �7 days), viral load, and type of RT-PCR used.

In an effort to use as much of the heterogeneous data as possible, the cutoffs for the Ct value groups were relaxed by 2-3 points within each range. The <20 group included values reported up to �20, the <25 group included values reported as �24 or <25 or 20-25, and the <30 group included values from �29 to �33 and 25-30. The �25 group included values reported as �25 or 25-30, and the �30 group included values from �30 to �35. For the same reason, when categorizing by age, the age group <18 years (children) included samples from persons whose age was reported as <16 or <18 years, whereas the age group �18 years (adults) included samples from persons whose age was reported as �16 years or �18.

For categorization by sample type, we assessed (1) nasopharyngeal (NP) alone or combined with other (e.g., oropharyngeal [OP]), (2) OP alone, (3) anterior nasal (AN) or mid-turbinate (MT), (4) a combination of bronchoalveolar lavage and throat wash (BAL/TW), or (5) saliva. Analyses were preformed using R 4.0.3 (R Foundation for Statistical Computing, Vienna, Austria).

We aimed to do meta-regression to examine the impact of covariates including symptom duration and Ct value range. We also performed the Deeks test for funnel-plot asymmetry as recommended to investigate publication bias for diagnostic test accuracy meta-analyses [18] (using the "midas" command in Stata, version 15); a p-value < 0.10 for the slope coefficient indicates significant asymmetry.

Two types of sensitivity analyses were planned: estimation of sensitivity and specificity excluding case-control studies, and estimation of sensitivity and specificity excluding nonpeer-reviewed studies. We compared the results of each sensitivity analysis against the overall results to assess the potential bias introduced by considering case-control studies and non-peer-reviewed studies.

The systematic search resulted in 14,254 articles. After removing duplicates, 8,921 articles were screened, and 266 papers were considered eligible for full-text review. Of these, 148 were excluded because they did not present primary data [13, or the Ag-RDT was not commercially available [16, , leaving 133 studies to be included in the systematic review (Fig 1) [4, .

At the end of the data extraction process, 37 studies were still in preprint form [4, 171, 173, 174, 177, 180, 190, 192, 201, 204, 205, 207, 211, [214] [215] [216] 218, 220, 222, 223, 225, 227, 231, 233, 234, 238, 240, 244, 247, 253, 257, 265, 267, 284, 287, 290, 293] . All studies were written in English, except for 2 in Spanish [175, 280] . Out of the 133 studies, 9 reported analytical accuracy [173, 191, 198, 208, 227, 256, 274, 275, 282] , and the remaining 124 reported clinical accuracy.

The clinical accuracy studies were divided into 214 datasets, while the 9 analytical accuracy studies accounted for 63 datasets. A total of 61 different Ag-RDTs were evaluated (48 lateral flow with visual readout and 12 requiring an automated reader), with 56 being assessed in a clinical accuracy study. Thirty-nine studies reported data for more than 1 test, and 19 of these studies conducted a head-to-head assessment, i.e., testing at least 2 Ag-RDTs on the same sample or participant. The reference method was RT-PCR in all except 1 study, which used viral culture [281] .

The most common reasons for testing were the occurrence of symptoms (55/19.9% of datasets), screening independent of symptoms (19/6.9%), and close contact with a SARS-CoV-2 confirmed case (10/3.6%). In 79 (28.6%) of the datasets, persons were tested due to more than 1 of these reasons, and for 163 datasets (59.1%), the reason for testing was unclear.

In total, 113, 242 

The findings on study quality using the QUADAS-2 tool are presented in Figs 2 and 3. In 190 (88.8%) datasets a relevant patient population was assessed. However, for only 44 (20.6%) of the datasets was patient selection considered representative of the setting and population chosen (i.e., they avoided inappropriate exclusions and a case-control design, and enrollment occurred consecutively or randomly).

The conduct and interpretation of the index tests was considered to have low risk for introduction of bias in 113 (52.8%) datasets (through, e.g., appropriate blinding of persons interpreting the visual readout). However, for 99 (46.3%) datasets, sufficient information to clearly judge the risk of bias was not provided. In only 89 (41.6%) datasets were the Ag-RDTs performed according to IFU, while 100 (46.7%) were not IFU-conforming, potentially impacting the diagnostic accuracy (for 25 [11. 7%] datasets the IFU status was unclear).

In 81 (37.9%) datasets, the reference standard was performed before the Ag-RDT, or the operator conducting the reference standard was blinded to the Ag-RDT results, resulting in a low risk of bias. In almost all other datasets (132/61.7%), this risk could not be assessed due to missing data. The applicability of the reference test was judged to be of low concern for all datasets, as cell culture and RT-PCR are expected to adequately define the target condition.

In 209 (97.7%) datasets, the sample for the index test and reference test were obtained at the same time, while this was unclear in 5 (2.3%) datasets. All samples included in a dataset were subjected to the same type of RT-PCR in 145 (67.8%) datasets, while different types of RT-PCR were used within the same dataset in 50 (23.4%) datasets. For 19 (8.9%) datasets, it was unclear. Furthermore, for 11 (5.1%) datasets, there was a concern that not all selected patients were included in the analysis.

Finally, 32 (24.1%) of the studies received financial support from the Ag-RDT manufacturer, and in another 9 (6.8%) studies, employment of the authors by the manufacturer of the Ag-RDT studied was indicated. Overall, a competing interest was found in 33 (24.8%) of the studies.

Out of 214 clinical datasets (from 124 studies), 20 were excluded from the meta-analysis because they included fewer than 20 RT-PCR positive samples. A further 21 datasets were missing either sensitivity or specificity and were only considered for univariate analyses. Across the remaining 173 datasets, including any test and type of sample, the pooled sensitivity and specificity were 71.2% (95% CI 68.2% to 74.0%) and 98.9% (95% CI 98.6% to 99.1%), respectively. If testing was performed in conformity with IFU, sensitivity increased to 76.3% (95% CI 73.1% to 79.2%), while non-IFU-conforming testing had a sensitivity of 65.9% (95% 

Based on 119 datasets with 71,424 tests performed, we were able to perform bivariate metaanalysis of the sensitivity and specificity for 12 different Ag-RDTs (Fig 4) . Across these, the pooled estimates of sensitivity and specificity on all samples were 72.1% (95% CI 68.8% to Datasets with an underlined reference and first author had not undergone peer-review yet at the time of data extraction (1 May 2021). In datasets with an underlined sample size, the samples were used in head-to-head studies, i.e., performing different Ag-RDTs on the same patient. � Values differ from those provided in the respective paper due to missing or contradictory data. A list including the original data can be found in S2 Three Ag-RDTs did not have sufficient data to allow for a bivariate meta-analysis, so a univariate analysis was conducted (Fig 5) . For the INNOVA SARS-CoV-2 Antigen Rapid Qualitative Test by Innova Medical Group (California, US), this resulted in a pooled sensitivity and specificity of 76.1% (95% CI 68.1% to 84.1%) and 99.4% (95% CI 98.7% to 100%), respectively. For the NADAL by nal von minden (Germany) and the COVID-19 Rapid Antigen Visual Read by SureScreen Diagnostics (UK), sufficient data were available to analyze only sensitivity, resulting in pooled sensitivity estimates of 58.4% (95% CI 29.2% to 87.6%) and 58.0% (95% CI 38.3% to 77.6%), respectively. 

The remaining 35 Ag-RDTs did not present sufficient data for univariate or bivariate metaanalysis. However, 9/35 had results presented in more than 1 dataset, and these are summarized in Table 2 . Herein, the widest ranges of sensitivity were found for the ESPLINE SARS-CoV-2 by Fujirebio (Japan), with sensitivity reported between 8.1% and 80.7%, and the RIDA QUICK SARS-CoV-2 Antigen by R-Biopharm (Germany), with sensitivity between 39.2% and 77.6%, both with 3 datasets each. In contrast, 2 other tests with 2 datasets each showed the least variability in sensitivity: The Zhuhai Encode Medical Engineering SARS-CoV-2 Antigen Rapid Test (China) reported sensitivity between 74.0% and 74.4%, and the COVID-19 Rapid Antigen Fluorescent by SureScreen Diagnostics (UK) reported sensitivity between 60.3% and 69.0%. However, for both tests, both datasets originated from the same studies. Overall, the lowest sensitivity range was reported for the SARS-CoV-2 Antigen Rapid Test by MEDsan (Germany): 36.5% to 45.2% across 2 datasets. The specificity ranges were above 96% for most of the tests. A notable outlier was the 2019-nCov Antigen Rapid Test Kit by Shenzhen Bioeasy Biotechnology (China; henceforth called Bioeasy), reporting the worst, with a specificity as low as 85.6% in 1 study. Forest plots for the datasets for each Ag-RDT are provided in S3 Fig. The remaining 26 Ag-RDTs that were evaluated in 1 dataset only are included in Table 1 S3 Fig. In total, 16 studies, accounting for 53 datasets, conducted head-to-head clinical accuracy evaluations of different tests using the same samples from the same participants. These datasets have underlined sample sizes in Table 1 ; 15 such studies included more than 100 samples, and 

1 study included too few samples to draw clear conclusions [286] . Four studies performed their head-to-head evaluation as per manufacturers' instructions and on symptomatic patients. Across 3 of them, Standard Q (sensitivity 73.2% to 91.2%) and Standard Q nasal (sensitivity 82.5% to 91.2%) showed a similar range of sensitivity [207, 215, 271] . The fourth reported a sensitivity of 56.4% (95% CI 44.7% to 67.6%) for the Biocredit Covid-19 Ag by RapiGEN (South Korea; henceforth called Rapigen) and 52.6% (95% CI 40.9% to 64.0%) for the SGTi-flex COVID-19 Ag by Sugentech (South Korea) [233] .

All other head-to-head comparisons were not IFU-conforming. In one of these, the Rapid COVID-19 Ag Test by Healgen (sensitivity 77.1%) performed better than Standard Q and Panbio (sensitivity 69.8% and 67.7%, respectively) [178] . In contrast to the overall findings of the meta-analysis above, 2 other head-to-head studies found that both Standard Q (sensitivity 43.6% and 49.4%) and Panbio (sensitivity 38.6% and 44.6%) had lower performance than the CLINITEST Rapid COVID-19 Antigen Test by Siemens Healthineers (Germany; henceforth called Clinitest), with reported sensitivity of 51.5% and 54.9% [167, 279] . However, another study found both Standard Q and Panbio (sensitivity 81.0% and 82.9%, respectively) to have a higher accuracy than Sofia (sensitivity 80.4%) [196] .

The results are presented in Figs 6 86 .9%) and 20.9% (95% CI 12.5% to 32.8%), respectively (Fig 6) . ). This was confirmed by 2 studies that reported direct head-to-head comparison of NP and MT samples from the same participants using the same Ag-RDT (Standard Q), where the 2 sample types showed equivalent performance [271, 272] . Analysis of performance with an OP swab (7 datasets, 5,165 samples) showed a pooled sensitivity of only 53.1% (95% CI 40.9% to 65.0%). Saliva swabs (4 datasets, 1,088 samples) showed the lowest pooled sensitivity, at only 37.9% (95% CI 11.8% to 73.5%) (Fig 8) .

We were not able to perform a subgroup meta-analysis for BAL/TW due to insufficient data: There was only 1 study with 73 samples evaluating Rapigen, Panbio, and Standard Q [286] . However, BAL/TW would in any case be considered an off-label use.

Subgroup analysis in symptomatic and asymptomatic patients. Within the datasets possible to meta-analyze, 17,964 (54.1%) samples were from symptomatic, and 15,228 (45.9%) from asymptomatic, patients. The pooled sensitivity for symptomatic patients was markedly different from that of asymptomatic patients: 76.7% (95% CI 70.6% to 81.9%) versus 52.5% (95% CI 43.7% to 61.1%). Specificity was 99% for both groups (Fig 9) . Median Ct values differed in symptomatic and asymptomatic patients. For those studies where it was possible to extract a median Ct value, it ranged from 20.5 to 27.0 in symptomatic patients [170, 207, 226, 258, 271, 272] and from 27.2 to 30.5 in asymptomatic patients [170, 201, 258] .

Subgroup analysis comparing symptom duration. Data were analyzed for 5,538 patients with symptoms less than 7 days, but very limited data were available for patients with symptoms �7 days (397 patients). The pooled sensitivity for patients with onset of symptoms <7 days was 83.8% (95% CI 76.3% to 89.2%), which is markedly higher than the 61.5% (95% CI 52.2% to 70.0%) sensitivity for individuals tested �7 days from onset of symptoms (Fig 9) .

Subgroup analysis by age. For adult patients (age � 18 years), it was possible to pool estimates across 3,837 samples, whereas the pediatric group (age < 18 years) included 7,326 samples. Sensitivity and specificity were 64.3% (95% CI 54.7% to 72.9%) and 99.4% (95% CI 98.9% to 99.7%), respectively, in mostly symptomatic patients aged <18 years. In patients aged �18 years, sensitivity increased to 74.8% (95% CI 66.5% to 81.6%), while the specificity was similar (98.7%, 95% CI 97.2% to 99.4%) (Fig 10) .

Subgroup analysis by type of RT-PCR and viral load. We were not able to perform a meta-analysis for the subgroups by type of RT-PCR or viral load (viral copies/mL) due to insufficient data.

In 152 (71.0%) of the datasets only 1 type of RT-PCR was used, whereas 37 (17.3%) of the datasets tested samples in the same dataset using different RT-PCR methods. For 25 (11.7%) of the datasets, the type of RT-PCR was not reported. The Cobas SARS-CoV-2 Test from Roche (Germany) was used most frequently, in 63 (29.4%) of the datasets, followed by the Allplex 2019-nCoV Assay from Seegene in 41 (19.2%) and the SARS-CoV-2 assay from TaqPath in 20 (9.3%) of the datasets.

Median sensitivity was 72.4% (range 46.9% to 100%) in samples with viral load > 5 log10 copies/mL, 97.8% (range 71.4% to 100%) for >6 log10 copies/mL, and 100% (range 93.8% to 100%) for >7 log10 copies/mL, showing that the sensitivity increases with increasing viral load.

Meta regression. We were not able to perform a meta-regression due to the considerable heterogeneity in reporting subgroups, which resulted in too few studies with sufficient data for comparison.

Publication bias. The result of the Deeks test (p = 0.001) shows significant asymmetry in the funnel plot for all datasets with complete results. This indicates there may be publication bias from studies with small sample sizes. The funnel plot is presented in S10 Fig. 

The 9 analytical studies were divided into 63 datasets, evaluating 23 different Ag-RDTs. Only 7 studies reported a sample size, for which 833 (90.6%) samples originated from NP swabs, while for 86 (9.4%) the sample type was unclear. One of the 2 studies not reporting sample size used saliva samples [198] , while the other used the sample type specified in the respective Ag-RDT's IFU [173] .

Overall, the reported analytical sensitivity (limit of detection [LOD] ) in the studies resembled the results of the meta-analysis presented above. Rapigen (LOD, in log10 copies per swab: 10.2) and Coris (LOD 7.46) were found to perform worse than Panbio (LOD 6.6 to 6.1) and Standard Q (LOD 6.8 to 6.0), whereas Clinitest (LOD 6.0) and BinaxNOW by Abbott (LOD 4.6 to 4.9) performed better [191, 256, 282] . Similar results were found in another study, where Standard Q showed the lowest LOD (detecting virus up to what is an equivalent Ct value of 26.3 to 28.7), compared to that of Rapigen and Coris (detecting virus up to what is an equivalent Ct value of only 18.4 for both) [208, 274, 275] . However, another study found Panbio, Standard Q, Coris, and BinaxNOW to have a similar LOD values of 5.0 × 10 3 plaque forming units (PFU)/mL, but the ESPLINE SARS-CoV-2 by Fujirebio (Japan), the COVID-19 Rapid Antigen Test by Mologic (UK), and the Sure Status COVID-19 Antigen Card Test by Premier Medical Corporation (India) performed markedly better (LOD 2.5 × 10 2 to 5.0 × 10 2 PFU/mL) [173] . An overview of all LOD values reported in the studies can be found in S3 Table.

When the datasets from case-control studies (25/173) were excluded, the estimated sensitivity did not differ greatly, with a value of 70.9% (95% CI 67.7% to 73.9%), compared to 71.2% (95% CI 68.2% to 74.0%) in the overall analysis, with no change in pooled specificity. When the datasets from preprints (64/173) were excluded, sensitivity decreased slightly, to 67.2% (95% CI 62.9% to 71.3%), compared to the overall analysis.

In this comprehensive systematic review and meta-analysis, we have summarized the data of 133 studies evaluating the accuracy of 61 different Ag-RDTs. Across all meta-analyzed samples, our results show a pooled sensitivity and specificity of 71.2% (95% CI 68.2% to 74.0%) and 98.9% (95% CI 98.6% to 99.1%), respectively. Over half of the studies did not perform the Ag-RDT in accordance with the test manufacturers' recommendation, or the performance was unknown, which negatively impacted the sensitivity. When we considered only IFU-conforming studies, the sensitivity increased to 76.3% (95% CI 73.1% to 79.2%). While we found the sensitivity to vary across specific tests, the specificity was consistently high.

The 2 Ag-RDTs that have been approved through the WHO emergency use listing procedure, Abbott Panbio and SD Biosensor Standard Q (distributed by Roche in Europe), have not only drawn the largest research interest, but also perform at or above average when their pooled accuracy is compared to that of all Ag-RDTs (sensitivity of 71.8% for Panbio and 74.9% for Standard Q). Standard Q nasal demonstrated an even higher pooled sensitivity (80.2% compared to the NP test), although this is likely due to variability in the populations tested, as head-to-head performance showed a comparable sensitivity. Three other Ag-RDTs showed an even higher accuracy, with sensitivities ranging from 77.4% to 88.2% (namely Sofia, Lumipulse G, and LumiraDx), but were only assessed on relatively small samples sizes (ranging from 1,373 to 3,532), and all required an instrument/reader.

Not surprisingly, lower Ct values, the RT-PCR semi-quantitative correlate for high virus concentration, resulted in significantly higher Ag-RDT sensitivity than higher Ct values (pooled sensitivity 96.5% and 95.8% for Ct value < 20 and <25, respectively, versus 50.7% and 20.9% for Ct value � 25 and �30, respectively). This confirms prior data that suggested that antigen concentrations and Ct values were highly correlated in NP samples [16] . Ag-RDTs also showed higher sensitivity in patients within 7 days after symptom onset compared to patients later in the course of the disease (pooled sensitivity 83.8% versus 61.5%), which is to be expected given that samples from patients within the first week after symptom onset have been shown to contain the highest virus concentrations [298] . In line with this, studies reporting an unexpectedly low overall sensitivity either shared a small population size with an on average high Ct value [230, 273, 288] or performed the Ag-RDT not as per IFU, e.g., using saliva or prediluted samples [167, 170, 203, 248, 279] . In contrast, studies with an unusually high Ag-RDT sensitivity were based on study populations with a low median Ct value, between 18 and 22 [189, 255, 284] .

Our analysis also found that the accuracy of Ag-RDTs is substantially higher in symptomatic patients than in asymptomatic patients (pooled sensitivity 76.7% versus 52.5%). This is not surprising as studies that enrolled symptomatic patients showed a lower range of median Ct values (i.e., higher viral load) than studies enrolling asymptomatic patients. Given that other studies found symptomatic and asymptomatic patients to have comparable viral loads [299, 300] , the differences found in our analysis are likely explained by the varied time in the course of the disease at which testing is performed in asymptomatic patients presenting for one-time screening testing. Because symptoms start in the early phase of the disease, when viral load is still high, studies testing only symptomatic patients have a higher chance of including patients with high viral loads. In contrast, study populations drawn from only asymptomatic patients have a higher chance of including patients at any point of disease (i.e., including late in disease, when PCR is still positive, but viable virus is rapidly decreasing) [301] .

With regards to the sampling and testing procedure, we found Ag-RDTs to perform similarly across upper respiratory swab samples (e.g., NP and AN/MT), particularly when considering the most reliable comparisons from head-to-head studies.

Similar to previous assessment [7] , the methodological quality of the included studies revealed a very heterogenous picture. In the future, aligning the design of clinical accuracy studies with common agreed-upon minimal specifications (e.g., by WHO or the European Centre for Disease Control and Prevention) and reporting the results in a standardized way [302] would improve data quality and comparability.

The main strengths of our study lie in its comprehensive approach and continuous updates. By linking this review to our website, https://www.diagnosticsglobalhealth.org, we strive to equip decision makers with the latest research findings on Ag-RDTs for SARS-CoV-2 and, to the best of our knowledge, are the first in doing so. At least once per week the website is updated by continuing the literature search and process described above. We plan to update the meta-analysis on a monthly basis and publish it on the website. Furthermore, our study used rigorous methods as both the study selection and data extraction were performed by one author and independently validated by a second, we conducted blinded pilot extractions before of the actual data extraction, and we prepared a detailed interpretation guide for the QUA-DAS-2 tool.

The study may be limited by the inclusion of both preprints and peer-reviewed literature, which could affect the quality of the data extracted. However, we aimed to balance this potential effect by applying a thorough assessment of all clinical studies included, utilizing the QUA-DAS-2 tool, and performing a sensitivity analysis excluding preprint manuscripts. In addition, the studies included in our analysis varied widely in the reported range of viral loads, limiting the comparability of their results. To control for this, we analyzed the Ag-RDTs' performance at different levels of viral load. Finally, even though we are aware that further data exist from other sources, for example from governmental research institutes [303] , such data could not be included because sufficiently detailed descriptions of the methods and results are not publicly available.

In summary, it can be concluded that there are Ag-RDTs available that have high sensitivity for the detection of a SARS-CoV-2 infection-particularly when performed in the first week of illness, when viral load is high-and excellent specificity. However, our analysis also highlights the variability in results between tests (which is not reflected in the manufacturer-reported data), indicating the need for independent validations. Furthermore, the analysis highlights the importance of performing tests in accordance with the manufacturers' recommended procedures, and in alignment with standard diagnostic evaluation and reporting guidelines. The accuracy achievable by the best-performing Ag-RDTs, combined with the rapid turnaround time compared to RT-PCR, suggests that these tests could have a significant impact on the pandemic if applied in thoughtful testing and screening strategies. 

World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays: interim guidance

Rethinking Covid-19 test sensitivity-a strategy for containment

Antigen-Tests auf SARS-CoV-2. Bonn: Federal Institute for Drugs and Medical Devices

Evaluation of the accuracy, ease of use and limit of detection of novel, rapid, antigen-detecting point-of-care diagnostics for SARS-CoV-2. medRxiv

Promise versus reality: optimism bias in package inserts for tuberculosis diagnostics

Advice on the use of point-of-care immunodiagnostic tests for COVID-19: scientific brief

Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection

COVID-19 rapid diagnostic test could contain transmission in low-and middle-income countries

COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil

Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays

Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection

Meta-analysis of the clinical performance of commercial SARS-CoV-2 nucleic acid, antigen and antibody tests up to 22

Real-world clinical performance of commercial SARS-CoV-2 rapid antigen tests in suspected COVID-19: a systematic meta-analysis of available data as per

Cochrane Diagnostic Test Accuracy Working Goup. Systematic reviews of diagnostic test accuracy

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

SARS-CoV-2 diagnosis

Real world performance of SARS-CoV-2 antigen rapid diagnostic tests in various clinical settings. medRxiv

Ultrasensitive assay for saliva-based SARS-CoV-2 antigen detection. medRxiv

Comparison of nasopharyngeal samples for SARS-CoV-2 detection in a paediatric cohort

Evaluation of SARS-CoV-2 antigen-based rapid diagnostic kits in Pakistan: formulation of COVID-19 national testing strategy

Longitudinal assessment of diagnostic test performance over the course of acute SARS-CoV-2 infection. medRxiv

Real-world clinical performance of the Abbott Panbio with nasopharyngeal, throat and saliva swabs among symptomatic individuals with COVID-19. medRxiv

Comparative evaluation of four SARS-CoV-2 antigen tests in hospitalized patients

Performance of qualitative and quantitative antigen tests for SARS-CoV-2 in early symptomatic patients using saliva. medRxiv

Rapid antigen test for postmortem evaluation of SARS-CoV-2 carriage

Development and performance characteristics evaluation of a new Bioelectric Recognition Assay (BERA) method for rapid Sars-CoV-2 detection in clinical samples

The limit of detection matters: the case for benchmarking severe acute respiratory syndrome coronavirus 2 testing

Discrepancy in screening performances of different rapid test kits for SARS-CoV-2; a letter to editor

Weekly SARS-CoV-2 screening of asymptomatic students and staff to guide and evaluate strategies for safer in-person learning. medRxiv

Salivary SARS-CoV-2 antigen rapid detection: a prospective cohort study

Comparative diagnostic performance of different rapid antigen detection tests for COVID-19 in the real-world hospital setting

ImplemeNting SARS-CoV-2 Rapid antigen testing in the Emergency wArd of a Swiss univErsity hospital: the INCREASE study

The dark side of SARS-CoV-2 rapid antigen testing: screening asymptomatic patients. medRxiv

Performance of a rapid antigen test in the diagnosis of SARS-CoV-2 infection

Limit of detection in different matrices of nineteen commercially available rapid antigen tests for the detection of SARS-CoV-2. medRxiv

Emergence of N antigen SARS-CoV-2 genetic variants escaping detection of antigenic tests. medRxiv

Experience with Panbio™ rapid antigens test device for the detection of SARS-CoV-2 in nursing homes

A rapid, high-sensitivity SARS-CoV-2 nucleocapsid immunoassay to aid diagnosis of acute COVID-19 at the point of care: a clinical performance study

Evaluation of the Panbio™ COVID-19 Ag Rapid Test at an emergency room in a hospital in São Paulo, Brazil. medRxiv

Head-to-head comparison of rapid and automated antigen detection tests for the diagnosis of SARS-CoV-2 infection

Validation testing to determine the sensitivity of lateral flow testing for asymptomatic SARS-CoV-2 detection in low prevalence settings: testing frequency and public health messaging is key

COVID-19 rapid antigen test at hospital admission associated to the knowledge of individual risk factors allow overcoming the difficulty of managing suspected patients in hospitals COVID-19 rapid antigen test facilitates the management of suspected patients on hospital admission. medRxiv

Foundation for Innovative New Diagnostics. FIND evaluation of Boditech Medical, Inc. iChroma COVID-19 Ag Test

SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold)

Foundation for Innovative New Diagnostics. FIND evaluation of Fujirebio Inc. Espline SARS-CoV-2. External Report Version 10

Foundation for Innovative New Diagnostics. FIND evaluation of Mologic Ltd, COVID 19 RAPID ANTI-GEN TEST

Foundation for Innovative New Diagnostics. FIND evaluation of NADAL COVID-19 Ag Rapid Test

Evaluation of automated test Lumipulse G SARS-CoV-2 antigen assay for detection of SARS-CoV-2 nucleocapsid protein (NP) in nasopharyngeal swabs for community and population screening

Differences in detected viral loads guide use of SARS-CoV-2 antigen-detection assays towards symptomatic college students and children. medRxiv

Impaired performance of SARS-CoV-2 antigen-detecting rapid diagnostic tests at elevated and low temperatures

An optimized stepwise algorithm combining rapid antigen and RT-qPCR for screening of COVID-19 patients. medRxiv

Prospective study of 1,308 nasopharyngeal swabs from 1,033 patients using the LUMIPULSE SARS-CoV-2 antigen test: comparison with RT-qPCR

Five antigen tests for SARS-CoV-2: virus viability matters

Diagnostic accuracy and utility of SARS-CoV-2 antigen lateral flow assays in medical admissions with possible COVID-19

Evaluation of three rapid lateral flow antigen detection tests for the diagnosis of SARS-CoV-2 infection

Performance of the BinaxNOW

Antigen Card test relative to the SARS-CoV-2 real-time reverse transcriptase polymerase chain reaction assay among symptomatic and asymptomatic healthcare employees. Infect Control Hosp Epidemiol

Detection of the new SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in five SARS-CoV-2 rapid antigen tests (RATs), Germany

SARS-CoV2 antigen in whole mouth fluid may be a reliable rapid detection tool

Comparison of four PCR and two point of care assays used in the laboratory detection of SARS-CoV-2

Accuracy of antigen and nucleic acid amplification testing on saliva and naopharyngeal samples for detection of SARS-CoV-2 in ambulatory care. medRxiv

Evaluation of performance of the BD Veritor SARS-CoV-2 chromatographic immunoassay test in patients with symptoms of COVID-19

The comparative clinical performance of four SARS-CoV-2 rapid antigen tests and their correlation to infectivity in vitro

Evaluation of accuracy, exclusivity, limit-of-detection and ease-of-use of LumiraDx™-Antigen-detecting point-of-care device for SARS-CoV-2. medRxiv

Diagnostic accuracy of SARS-CoV-2 rapid antigen detection testing in symptomatic and asymptomatic children in the clinical setting. medRxiv

Comparison of the quantitative DiaSorin Liaison antigen test to RT-PCR for the diagnosis of COVID-19 in symptomatic and asymptomatic outpatients

SARS-CoV-2 patient self-testing with an antigen-detecting rapid test: a head-to-head comparison with professional testing. medRxiv

Evaluation of rapid antigen detection kit from the WHO Emergency Use List for detecting SARS-CoV-2

Analytical performances of the point-of-care SIENNA™ COVID-19 Antigen Rapid Test for the detection of SARS-CoV-2 nucleocapsid protein in nasopharyngeal swabs: a prospective evaluation during the COVID-19 second wave in France

Lumipulse G SARS-CoV-2 Ag Assay evaluation for SARS-CoV-2 antigen detection using 594 nasopharyngeal swab samples from different testing groups

Point of care testing using rapid automated antigen testing for SARS-COV-2 in care homes-an exploratory safety, usability and diagnostic agreement evaluation. medRxiv

SARS-CoV-2 antigen rapid immunoassay for diagnosis of COVID-19 in the emergency department

Multi-site assessment of rapid, point-of-care antigen testing for the diagnosis of SARS-CoV-2 infection in a low-prevalence setting: a validation and implementation study

Diagnostic accuracy of Panbio rapid antigen tests on oropharyngeal swabs for detection of SARS-CoV-2. medRxiv

Anterior nasal versus nasal midturbinate sampling for a SARS-CoV-2 antigen-detecting rapid test: does localisation or professional collection matter? medRxiv

Multicenter evaluation of a fully automated high-throughput SARS-CoV-2 antigen immunoassay. medRxiv

Performance characteristics of BinaxNOW COVID-19 Antigen Card for screening asymptomatic individuals in a university setting

Diagnostic accuracy of a novel SARS-CoV-2 antigen-detecting rapid diagnostic test from standardized self-collected anterior nasal swabs. medRxiv

Evaluation of two rapid antigen tests to detect SARS-CoV-2 in a hospital setting

Performance of SARS-CoV-2 rapid antigen test compared with real-time RT-PCR in asymptomatic individuals. medRxiv

Diagnostic performance of CerTest and Panbio antigen rapid diagnostic tests to diagnose SARS-CoV-2 infection

COVID-19: rapid antigen detection for SARS-CoV-2 by lateral flow assay: a national systematic evaluation for mass-testing. medRxiv

Comparative performance of SARS-CoV-2 lateral flow antigen tests demonstrates their utility for high sensitivity detection of infectious virus in clinical specimens. medRxiv

Performance and implementation evaluation of the Abbott BinaxNOW Rapid Antigen Test in a high-throughput drive-through community testing site in Massachusetts

Performance and operational evaluation of the Access Bio CareStart Rapid Antigen Test in a high-throughput drive-through community testing site in Massachusetts. medRxiv

Validation of the STANDARD Q COVID-19 antigen test in Vojvodina, Serbia

Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests. medRxiv

Rapid antigen detection testing for universal screening for severe acute respiratory syndrome coronavirus 2 in women admitted for delivery

Clinical assessment of the Roche SARS-CoV-2 rapid antigen test. Diagnosis (Berl)

Immunochromatographic test for the detection of SARS-CoV-2 in saliva

Diagnostic accuracy of rapid antigen tests in pre-/asymptomatic close contacts of individuals with a confirmed SARS-CoV-2 infection. medRxiv

Evaluation of rapid antigen tests based on saliva for the detection of SARS-CoV-2

The value of rapid antigen tests to identify carriers of viable SARS-CoV-2. medRxiv

Self-testing for the detection of SARS-CoV-2 infection with rapid antigen tests. medRxiv

Clinical performance of the Abbott Panbio with nasopharyngeal, throat, and saliva swabs among symptomatic individuals with COVID-19

Performance of a point-of-care test for the rapid detection of SARS-CoV-2 antigen

The evaluation of a newly developed antigen test (QuickNavi™-COVID19 Ag) for SARS-CoV-2: a prospective observational study in Japan

Diagnostic performance and characteristics of anterior nasal collection for the SARS-CoV-2 antigen test: a prospective study

Utility of antigen-based rapid diagnostic test for detection of SARS-CoV-2 virus in routine hospital settings

Evaluation of a novel, rapid antigen detection test for the diagnosis of SARS-CoV-2. medRxiv

Point-of-care evaluation of a rapid antigen test (CLINITEST ® Rapid COVID-19 Antigen Test) for diagnosis of SARS-CoV-2 infection in symptomatic and asymptomatic individuals

Clinical application of a rapid antigen test for the detection of SARS-CoV-2 infection in symptomatic and asymptomatic patients evaluated in the emergency department: a preliminary report

Diagnostic accuracy of the Panbio SARS-CoV-2 Antigen Rapid Test compared with RT-PCR testing of nasopharyngeal samples in the pediatric population

Clinical performance evaluation of SARS-CoV-2 rapid antigen testing in point of care usage in comparison to RT-qPCR. medRxiv

SARS-CoV-2 diagnostic tests: algorithm and field evaluation from the near patient testing to the automated diagnostic platform

Use of lateral flow devices allows rapid triage of patients with SARS-CoV-2 on admission to hospital

Comparison of SARS-COV-2 nasal antigen test to nasopharyngeal RT-PCR in mildly symptomatic patients

Evaluation of the rapid antigen test Panbio COVID-19 in saliva and nasal swabs: a population-based pointof-care study

Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres

Analytical and clinical performance of the Panbio COVID-19 antigen-detecting rapid diagnostic test

Comparison of Quidel Sofia SARS FIA Test to Hologic Aptima SARS-CoV-2 TMA Test for diagnosis of COVID-19 in symptomatic outpatients

Diagnostic accuracy of two commercial SARS-CoV-2 antigen-detecting rapid tests at the point of care in community-based testing centers

Evaluation of the Panbio™ rapid antigen test for SARS-CoV-2 in primary health care centers and test sites. medRxiv

Urgent need of rapid tests for SARS CoV-2 antigen detection: evaluation of the SD-Biosensor antigen test for SARS-CoV-2

Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand

Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests

The sensitivity of SARS-CoV-2 antigen tests in the view of large-scale testing. medRxiv

Evaluation of the Panbio Covid-19 rapid antigen detection test device for the screening of patients with Covid-19

Foundation for Innovative New Diagnostics

Foundation for Innovative New Diagnostics. FIND evaluation of RapiGEN Inc. BIOCREDIT

External Report Version 21

Foundation for Innovative New Diagnostics. FIND evaluation of SD Biosensor, Inc. STANDARD™ F COVID-19 Ag FIA

Foundation for Innovative New Diagnostics. FIND evaluation of SD Biosensor, Inc. STANDARD Q COVID-19 Ag Test

Real-life validation of the Panbio COVID-19 Antigen Rapid Test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection

Rapid chromatographic immunoassaybased evaluation of COVID-19: a cross-sectional, diagnostic test accuracy study & its implications for COVID-19 management in India

Testing of healthcare workers exposed to COVID19 with rapid antigen detection. medRxiv

Clinical evaluation of the Roche/SD Biosensor rapid antigen test with symptomatic, non-hospitalized patients in a municipal health service drive-through testing site

Evaluation of the accuracy and ease-of-use of Abbott PanBio-a WHO emergency use listed, rapid, antigen-detecting point-ofcare diagnostic test for SARS-CoV-2. medRxiv

Comparison of the SARS-CoV-2 rapid antigen test to the real star Sars-CoV-2 RT PCR kit

Evaluation of a rapid diagnostic assay for detection of SARS-CoV-2 antigen in nasopharyngeal swabs

Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms

Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with professional-collected nasal versus nasopharyngeal swab

Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swab versus professional-collected nasopharyngeal swab

Performance of a novel diagnostic assay for rapid SARS-CoV-2 antigen detection in nasopharynx samples

Analytical sensitivity and clinical sensitivity of the three rapid antigen detection kits for detection of SARS-CoV-2 virus

Evaluation of rapid antigen test for detection of SARS-CoV-2 virus

Multicenter evaluation of the Panbio™ COVID-19 Rapid Antigen-Detection Test for the diagnosis of SARS-CoV-2 infection

Development and potential usefulness of the COVID-19 Ag Respi-Strip diagnostic assay in a pandemic context

Field evaluation of the performance of a SARS-CoV-2 antigen rapid diagnostic test in Uganda using nasopharyngeal samples

Handling and accuracy of four rapid antigen tests for the diagnosis of SARS-CoV-2 compared to RT-qPCR

Usefulness of the antigen for diagnosing SARS-CoV-2 infection in patients with and without symptoms

Antigen-based testing but not real-time PCR correlates with SARS-CoV-2 virus culture

Analytical sensitivity of the Abbott BinaxNOW COVID-19 Ag CARD

Performance characteristics of a rapid SARS-CoV-2 antigen detection assay at a public plaza testing site in San Francisco

Rapid SARS-CoV-2 antigen detection by immunofluorescence-a new tool to detect infectivity. medRxiv

Evaluation of a novel antigenbased rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples

Limits and opportunities of SARS-CoV-2 antigen rapid tests-an experience based perspective

Antigen rapid tests, nasopharyngeal PCR and saliva PCR to detect SARS-CoV-2: a prospective comparative clinical trial. medRxiv

Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis

Sensitivity and specificity of lateral flow antigen test kits for COVID-19 in asymptomatic population of quarantine centre of province 3

SARS-CoV-2 qRT-PCR Ct value distribution in Japan and possible utility of rapid antigen testing kit. medRxiv

Evaluation of a SARS-CoV-2 rapid antigen test: potential to help reduce community spread?

Real-life evaluation of a rapid antigen test (Panbio COVID-19 Ag Rapid Test Device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients

Performance evaluation of a SARS-CoV-2 rapid antigentest: test performance in the community in the Netherlands. medRxiv

Diagnosis value of SARS-CoV-2 antigen/antibody combined testing using rapid diagnostic tests at hospital admission

Comparative evaluation of four rapid SARS-CoV-2 antigen detection tests using universal transport medium

Clinical evaluation of BD Veritor SARS-CoV-2 point-of-care test performance compared to PCR-based testing and versus the Sofia 2 SARS Antigen point-of-care test

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

SARS-CoV-2 viral dynamics in acute infections. medRxiv

Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the Republic of Korea

Comparison of upper respiratory viral load distributions in asymptomatic and symptomatic children diagnosed with SARS-CoV-2 infection in pediatric hospital testing programs

Post-disease divergence in SARS-CoV-2 RNA detection between nasopharyngeal, anterior nares and saliva/oral fluid specimens -significant implications for policy & public health. medRxiv

STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies

Comparative evaluation of the sensitivities of SARSCoV-2 antigen rapid tests Langen: Federal Institute for Vaccines and Biomedicines